卵巢癌腹水中血管内皮生长因子的表达及临床意义

摘要
图/表
参考文献
相关文章 (6)

全文: PDF (728 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨卵巢癌恶性腹水中血管内皮生长因子(VEGF)水平与临床病理因素之间的相关性。方法采用ELISA方法检测148例卵巢癌患者恶性腹水中VEGF的表达。结果卵巢癌组腹水中VEGF表达水平为(909.16±583.15)pg/ml,显著高于良性组的(258.13±127.82 )pg/ml,两组差异有统计学意义,其VEGF的表达与淋巴结转移及临床分期相关(P＜0.05)。VEGF高表达患者(≥613.38 pg/ml)的生存期[(9.98±0.68)月]明显低于VEGF含量低的(＜613.38 pg/ml)患者的生存期[(23.64±0.65)月],差异有统计学意义。多因素Cox回归分析结果显示腹水VEGF值与卵巢癌患者的生存期明显相关(P<0.001)。结论腹水VEGF值可成为卵巢癌患者独立预后指标。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	夏红慧
	詹娜

关键词 ：血管内皮生长因子, 卵巢癌恶性腹水, ELISA

Abstract：Objective To examine the expression and significance of vascular endothelial growth factor (VEGF) in ascitic fluid from patients with epithelial ovarian cancer.Methods The study included 148 consecutive ovarian cancer patients with malignant ascites. VEGF levels in ascites were determined by a sandwich enzyme-linked immunoadsorbent assay.Results In our study, we found VEGF levels in malignant ascites (909.16±583.15 pg/ml) were significantly higher than those in benign ascites (258.13 ± 127.82 pg/ml) (P＜0.001). Meanwhile, we also found that VEGF levels in malignant ascites were associated with TNM stage and lymphatic invasion. Patients with a high level of VEGF (≥613.38 pg/ml) in malignant ascites exhibited poor mean survival rate [(9.98±0.68) vs (23.64±0.65) months, P<0.001]. In a multivariate Cox regression model, higher ascites VEGF was an independent prognostic factor for overall survive.Conclusion The high level of VEGF value in malignant ascites may be used as an independent prognostic factor in patients with ovarian cancer.

Key words： Vascular endothelial growth factor Ovarian cancer Malignant ascites

收稿日期: 2015-10-21

基金资助:湖北省自然科学基金资助项目(2013CFB255)

引用本文:

夏红慧, 詹娜. 卵巢癌腹水中血管内皮生长因子的表达及临床意义[J]. 中国生育健康杂志, 2016, 27(2): 127-129.
XIA Honghui, ZHAN Na. The expression and significance of ascitic vascular endothelial growth factor in epithelial ovarian cancer. Chinese Journal of Reproductive Health, 2016, 27(2): 127-129.

链接本文:

http://cjrh.bjmu.edu.cn/CN/ 或 http://cjrh.bjmu.edu.cn/CN/Y2016/V27/I2/127

1 Fujimoto J,Toyoki H,Sato E,et al.Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers.Br J Cancer,2004,91:466-469.
2 Bikfalvi A.Significance of angiogenesis in tumour progression and metastasis.Eur J Cancer,1995,31A:1101-1104.
3 Matsuyama M,Chijiwa T,Inoue Y,et al.Alternative splicing variant of vascular endothelial growth factor-A is a critical prognostic factor in non-small cell lung cancer.Oncol Rep,2009,22:1407-1413.
4 Otrock ZK,Makarem JA,Shamseddine AI,et al.Vascular endothelial growth factor family of ligands and receptors:Review.Blood Cells Mol Dis,2007,38:258-268.
5 Raspollini MR,Amunni G,Villanucci A,et al.Prognostic significance ofmicrovessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma.Int J Gynecol Cancer,2004,14:815-823.
6 Goodheart MJ,Ritchie JM,Rose SL,et al.The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.Clin Cancer Res,2005,11:3733-3742.
7 Hefler LA,Zeillinger R,Grimm C,et al.Preoperative serum vascular endothelial growth factor as aprognostic parameter in ovarian cancer.Gynecol Oncol,2006,103:512-517.
8 Li L,Wang L,Zhang W,et al.Correlation of serum VEGF levels with clinical stage,therapy efficacy,tumor metastasis and patient survival in ovarian cancer.Anticancer Res,2004,24:1973-1979.
9 Rudlowski S,Pickarts AK,Fuhljahns TC,et al.Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients:a long-term follow-up.Int J Gynecol Cancer,2006,16:183-189
10 Alcutagawa N,Nishikama A,Iwasaki M,et al.Expression of vascular endothelial growth fact in human ovarian cancer association and peritoneal matastasis in house ascites model,cancer Res,2002,93:644-659.
11 Mendel DB,Laird AD,Smolich BD,et al.Development of SU5416,a selective tyrosine kinase inhibitor of vascular endothelial growth fact receptor tyrosine kinase activity,as anti-angiogenesis agent.Anticancer Drug Res,2000,15:29-41.
12 Verheul HM,Hoekman K,Jorna AS,et al.Targeting vascular endothelial growth factor blockade:ascites and pleural effusion formation.Oncologist,2000,1:S45-S50.
13 See HT,Kavanagh JJ,Hu W,et al.Targeted therapy for epithelial ovarian cancer:current status and future prospects.Int J Gynecol Cancer,2003,13:701-734

(